SCHEMBL21564643

SCHEMBL21564643

CCOC(=O)/C=C/c1cn(-c2ccc(F)cc2)c(=O)c(N2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.40
MAPT P10636 5/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
STAT3 P40763 1/20 0.40
STAT1 P42224 1/20 0.40
ENPP2 Q13822 1/20 0.40
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
ALDH1A1 P00352 1/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
GRM5 P41594 1/20 0.37
GRM1 Q13255 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
GABRA2 P47869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21553097 0.89 IDO1 (0.40) MAPTKMT2AMEN1STAT3STAT1
SCHEMBL21564477 0.88 KMT2A (0.40) MAPTKMT2AMEN1LMNAALDH1A1
SCHEMBL21564467 0.86 CNR1 (0.43) MAPTKMT2AMEN1STAT3STAT1
SCHEMBL23258619 0.84 MAPT (0.43) MAPTKMT2ALMNASMN1; SMN2HTT
SCHEMBL21564861 0.81 GRIA1 (0.41) GRIA1MAPTKMT2AMEN1ENPP2
SCHEMBL21564614 0.79 ALDH1A1 (0.39) MAPTKMT2AMEN1ALDH1A1NPC1
SCHEMBL21564785 0.78 GABRA2 (0.38) GRIA1MAPTKMT2AMEN1STAT3
SCHEMBL21564480 0.78 MAPT (0.39) MAPTKMT2AMEN1MAPK1HTT
SCHEMBL21564508 0.77 GRIA1 (0.42) GRIA1MAPTKMT2AMEN1ENPP2
SCHEMBL4719112 0.77 ABCB1 (0.56) MAPTKMT2AMEN1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112513020-B KDM1A inhibitors for the treatment of diseases 伊美格生物科学公司 2024-02-23 CN disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
CN-112513020-A KDM1A inhibitors for the treatment of disease 伊美格生物科学公司 2021-03-16 CN disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A GRIA1 2609/4885MAPT 4010/4885KMT2A 17/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A GRIA1 2330/4885MAPT 4054/4885KMT2A 17/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A GRIA1 2609/4885MAPT 4010/4885KMT2A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.